Discontinuing bDMARD treatment before orthopedic surgery may increase the risk for postoperative disease flares among patients with RA.

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

GRAPPA published treatment recommendations for PsA in 2009 based on evidence from systematic reviews and consensus of 70 rheumatologists and dermatologists with subspecialty expertise in management of ...

After the first 6 months of disease-modifying antirheumatic drugs (DMARDs) use in patients with rheumatoid arthritis (RA), most very abnormal results newly seen in long-term routine laboratory ...

Psoriatic arthritis is an autoimmune condition that causes joint inflammation, skin symptoms, and pain. People searching for psoriatic arthritis prescriptions are often looking for detailed ...

Changing the mechanism of action may offer more durable disease control for patients with PsA who do not respond to an initial TNF inhibitor.

According to a new study, paternal exposure to immunosuppressive and biologic antirheumatic drugs before conception has ...

In their "Impact of delay of treatment with disease-modifying antirheumatic drugs (DMARDs) in psoriatic arthritis: The CorEvitas psoriatic arthritis/spondyloarthritis registry," published in ACR Open ...

Use of conventional synthetic drugs to treat juvenile idiopathic arthritis (JIA) fell by half during 2000-2022, as targeted therapies became increasingly popular, analysis of commercial insurance ...

Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...